of the 2 isoforms depending on the tissue. Specifically, the long isoform is highly expressed in lungs, ovaries, testes, cerebellum, cortex, retina, pituitary gland, and olfactory bulbs, while the short isoform is highly expressed in mouse podocytes and in human podocyte cell lines, at both mRNA and protein levels. The silencing of ALG13-is2 by specific siRNAs induces an altered N-linked glycosylation pattern of nephrin, as demonstrated by the presence of an additional immunostaining band of about 130 kD. In knock-down cells, immunofluorescence analysis shows perturbed organization of the cytoskeleton and altered localization of nephrin on the cellular membrane. We also demonstrated that the altered pattern of N-linked glycosylation induces an over-expression of binding immunoglobulin protein and calreticulin, suggesting ER stress. Conclusions: These results provide preliminary evidence that ALG13-is2 could be an important modifier of renal filtration defects. Recently, we identified a missense variant (p.T141L) in the short isoform 2 of the X-linked gene asparagine-linked glycosylation 13 ( ALG13-is2 ), which segregated with focal segmental glomerulosclerosis and PCCD in a large Australian pedigree; however, any evidence of its pathogenicity was demonstrated. ALG13 gene encodes, through alternative splicing, 2 glycosyltransferase isoforms, which catalyse the second sugar addition of the highly conserved oligosaccharide precursor in the endoplasmic reticulum (ER). Mutations in the long isoform 1 were associated with epilepsy. Methods and Results: Here, we show a different expression
Introduction
Focal segmental glomerulosclerosis (FSGS) is a disorder of the glomerular filtration barrier, which consists of 3 layers [1] : (i) the glomerular endothelial cells, (ii) the glomerular basement membrane (GBM), and (iii) the podocytes, or visceral epithelial cells. Podocytes are highly specialised, terminally differentiated cells with cytoplasmic extensions; they constitute the so-called foot processes, which have an important role in size-and chargeselective permeability and also in synthesising and maintaining the GBM [2] . FSGS damages the glomerulus and allows proteins to leak into the urine (proteinuria). Over time, the damage to the kidney may cause kidney failure requiring dialysis or renal transplantation. Podocyte alterations (like foot process removal) are prominent in FSGS [3, 4] . Genes mutated in the familial forms of FSGS (e.g., ACTN4 , TRPC6 , CD2AP , NPHS1 , and NPHS2 ) encode podocyte proteins involved in the maintenance of glomerular slit diaphragms, which in turn, are responsible for holding back macromolecular structures like proteins within the vascular bed [5] [6] [7] [8] .
Recently, we identified an extended Australian family in which FSGS co-segregated with progressive heart block (PCCD) with apparent X-linked recessive inheritance. Two variants in 2 X-linked genes, NXF5-R113W and asparagine-linked glycosylation 13 (ALG13)-T141L, segregated perfectly with the disease phenotype in the pedigree and were not found in a large healthy control cohort. Analysis using bioinformatics tools predicted the R113W mutation in the NXF5 gene to be deleterious and cellular studies supported a role in the stability and localization of the protein suggesting a causative role [9] . The missense change p.T141L (rs397518473), located in the C-terminal region of the isoform 2 of the ALG13 protein (ALG13-is2), affects a highly evolutionarily conserved residue of the short isoform 2; however, SIFT software predicted a tolerated effect for this variant, and we were not able to establish a pathological role for this variant/gene (as reported in OMIM #300776) in our previous paper [9] . N-linked glycosylation, a post-translational modification process, has an important role to play in protein folding, intracellular trafficking and membrane targeting, as well as in regulating protein function. The alteration of the N-linked glycosylation in congenital nephrotic syndrome has been reported as a consequence of mutations in the N-linked glycosylation site of the nephrin, but little is known about the factors regulating this process in podocytes [10] . Here, we investigated if ALG13-is2 could be such a factor.
Methods
The complete Material and Methods section is reported in online supplementary data (for all online suppl. material, see www. karger.com/doi/10.1159/000455129). Quantitative real time PCRs (qPCRs) were performed as described in online supplementary methods and as previously reported [11, 12] . Primers used are listed in online supplementary Table 1 .
Results

ALG13 Gene Structure
The ALG13 gene is located on chromosome X; it spans a genomic region of 80 kb and is split in 32 exons. In the Ensembl database, at least 6 transcripts of the ALG13 gene are reported to be protein-coding, but only 2 -the transcripts 1 (NM_001099922) and 2 (NM_018466) -are highly conserved in all vertebrates. The 2 isoforms of ALG13 (ALG13-is1 and ALG13-is2) are identical at N-terminal region (125 amino acids), in which the catalytic domain is located, while they substantially differ in the C-terminal region ( Fig. 1 ) . In particular, the 2 isoforms originate from alternative splicing of the exon 6, which contains an in-frame stop codon and a 3 ′ UTR alternative region [9] . The exon 6 is removed in transcript 1, thus producing a long isoform of the protein, while it is kept in transcript 2, thus producing a short isoform in which the C-terminal region is highly conserved in mice (100% identity at nucleotide level; online suppl. Fig. 1a, b) . In fact, this region might be important to shuttle the ALG13 protein, which does not have a transmembrane domain, to the endoplasmic reticulum (ER). Bioinformatics prediction shows that the p.T141L mutation, associated with the FSGS-PCCD phenotype [9] , could alter the alpha-helix structure of this C-terminal region (online suppl. Fig. 2 ).
Expression Profile of the ALG13 Gene
The expression of the transcripts 1 and 2 of the ALG13 gene was evaluated by using 2 panels of human and mouse RNAs derived from adult tissues through qPCR assay. The 2 transcripts were ubiquitously expressed with the long isoform 1 being more abundant in almost all analysed tissues than the short isoform 2 with the exception of human liver, pancreas and kidney, where the isoform 2 was more expressed ( Fig. 2 a, b) . A predominantly high expression of ALG13is2 was disclosed in human and mouse podocyte cells when compared with different cell lines such as murine ES-derived cardiomyocytes, murine macrophage (Raw-264 celle line), human embryonic kidney (HEK-293) cells and proximal tubular cells (HK-2; Fig. 3 a, b) . This result suggests a potential role in podo-cytes for the short isoform 2. The high expression of ALG13-is2 in human and mouse podocytes ( Fig. 3 a, b ) led us to determine as to when its expression increases during the differentiation of human podocyte cell line [13] by performing a time course experiment. Data was compared to the expression of ALG13-is1 , and to nephrin, podocin and CD2AP genes, which are highly expressed in differentiated podocytes ( Fig. 3 c-e). Similar to nephrin, podocin and CD2AP , ALG13-is2 also increases during the differentiation of podocytes, reaching the maximum expression peak at 14 days of differentiation, at both RNA and protein levels ( Fig. 3 c-f ). Immunofluorescence staining was performed on serial sections of kidney and brain mice tissues. A predominantly high expression of Alg13 is1 was detected in brain regions involved in epilepsy, specifically in the cortex and in the areas CA1 and CA3 of the dorsal hippocampus and dentate gyrus (DG3; online suppl. Fig. 3a) , while the short isoform 2 was undetectable (data not shown). In the kidney both antibodies, anti-ALG13 is1 and anti-ALG13 is2 (Anti-GLT28D), intensely stain tubular cells; however, a slightly more intense signal in glomerulous and podocyte cells was observed for Fig. 3b ). However, it is important to consider that the antibody GLT28D is specific for the short isoform 2, while the antibody against the isoform 1 also stains the isoform 2.
Knock-Down of the Short Isoform 2 of the ALG13 Gene
Human nephrin has 10 potential N-linked glycosylation sites in its amino acid sequence, but its post-translational modification process in podocytes has not been investigated to date [14] . To assess if the short isoform of ALG13 is involved in this process, we performed its silencing by using a specific ALG13-is2 set of siRNA in human podocyte cell lines at 12 days of differentiation and in HEK-293 cells. Since nephrin is not expressed in the HEK-293 cell line, these cells were co-transfected with both nephrin plasmid and siRNA. The efficiency of the downregulation of ALG13-is2 was greater than 80% and was highly specific for the short isoform ( Fig. 4 a, b) . The effect of the ALG13-is2 knock-down on the N-linked glycosylation pattern of nephrin was assessed by Western blot. As reported in literature for nephrin expression [14] , 2 immunostaining bands of 200 and 180 kD were detected together with an additional band of about 130 kD, which was revealed both in the medium of podocytes (in which endogenous nephrin protein is detected; Fig. 4 c) and in the whole HEK293 cell lysate (in which the nephrin was transiently transfected; Fig. 4 e) ; this band has the same molecular weight as the non-glycosylated nephrin [14] . We cannot explain why in podocyte cells nephrin was detected only in the medium and not in the cytoplasm. In order to confirm that the additional immunostaining band of 130 kD is the hypoglycosylated nephrin and not one of degradation form, podocytes cells were incubated with tunicamycin (TUN), which specifically inhibits the first step of N-linked glycosylation obtaining the same immunostaining pattern of the siRNA treatment ( Fig. 4 d) . In this case, a longer time of boiling was applied to proteins to highlight the characteristic smear of glycosylated proteins. Both siRNA and TUN treatment gave a defective glycosylation pattern of nephrin because a smear spanning 200 to 130 kD was detected. Then, these proteins were immunoprecipitated with the antibody anti-nephrin and probed with concanavalin A, a lectin which is able to bind glycosylated proteins. A single immunostaining band of 180 kD was detected suggesting that the shorter 130 kD band is the hypoglycosylated nephrin ( Fig. 4 f) . Moreover, we showed that only the ALG13-is2 141T protein, but not the mutated ALG13-is2 141L protein, was able to rescue the hypoglycosylation of the nephrin, suggesting (i) a direct role of the short isoform 2 of ALG13 on the glycosylation of the nephrin and (ii) a direct relationship between the p.T141L mutation and the hypoglycosylation of the nephrin ( Fig. 4 d) . Additional data are required to assess how this mutation alters the N-linked glycosylation process. Since the altered glycosylation could affect the folding of the protein, we evaluated the expression of a panel of ER stress chaperons by qPCR in podocytes cells in which ALG13-is2 was silenced. We observed an increased expression of the binding immunoglobulin protein and calreticulin, which is suggestive of ER stress ( Fig. 4 g, h) . Immunofluorescence analysis performed on ALG13-is2 knock-down podocytes showed actin disorganization and reduced localization of nephrin on the cellular membrane (online suppl. Fig. 4 ). We were not able to show the presence of nephrin in the ER. Taken together, these data provide the first evidence that the short isoform of ALG13 plays an important role in podocytes being involved in the folding and localization of nephrin. This suggests its role as a modifier gene in nephrotic syndromes.
Discussion
ALG13 catalyses the second step of eukaryotic N-linked glycosylation in the ER [15] . The long isoform 1 (ALG13-is1) and the short isoform 2 (ALG13-is2) are identical in the N-terminal region, which contains the catalytic domain, while they substantially dif- and mouse podocytes, which were isolated from mouse glomeruli as described in our previous work [9] . c Expression of ALG13is2 and ALG13is1 during podocytes differentiation (0, 4, 8, and 14 days). d , e Expression of the podocyte markers: podocin, CD2AP and nephrin compared to the expression of ALG13 isoforms (1 and 2) during podocyte differentiation. The expression of all podocyte markers increases during podocytes differentiation of 4-6 fold; the ALG13-is2 isoform increases 10 fold. All qPCRs were performed in triplicate and normalised to HPRT mRNA levels except for mouse cells ( b ), which were normalized versus Gapdh. The mean ± SD of 3 independent experiments were plotted as histogram representation. Expression values are reported as folds of expression normalised to 1 at day 0 of differentiation ( c-e ); in a and b , expression data were reported as absolute values. The double asterisk ( * * ) indicates a p value <0.01. f Western blot analysis. Proteins were extracted from podocyte cells at a different time of differentiation and immuno-stained with anti-ALG13-is2 (GLT28D1 1: 500, ABCAM) and anti-nephrin (1: 500 Santa Cruz). The signals obtained for each protein were normalized to beta-actin. A high level of expression of the nephrin and ALG13-is2 is observed on the 14th day of differentiation. fer in the C-terminal region, which is important for transferring the protein to the ER. Mutations, which fall in the C-terminal region of ALG13-is1, cause congenital disorders of glycosylation type I, epileptic encephalopathies and nonsyndromic intellectual disability [16] [17] [18] . The p.T141L variant, located in the C-terminal alpha-helix region of the short isoform 2, was identified in all individuals affected by FSGS and PCCD of an extended Australian family [9] . In our previous paper, we were not able to identify a functional role for this variant [9] . Nevertheless, in this study, we report a high expression of the transcript 1 in neuronal tissues compared with the higher expression of the transcript 2 in podocytes, suggesting different phenotypes associated with mutations in the 2 isoforms. N-linked glycosylation, a post-translational modification process, has an important role to play in protein folding, intracellular trafficking and membrane targeting, as well as in regulating the protein function. Mutations affecting N-linked glycosylation sites of some podocyte proteins (e.g., nephrin and TRPC6) have been described in FSGS [10, 14, 19, 20] . In particular, it was demonstrated that N-linked glycosylation of nephrin is crucial for its proper folding and, consequently, its plasma membrane localization [14] . Here, we show that the short isoform of ALG13 could be an important player in this process and, therefore, its inhibition might trigger the onset of filtration defects of some acquired glomerular diseases.
FSGS is a podocyte disorder. Podocytes are highly specialised, terminally differentiated cells with cytoplasmic extensions, the so-called foot processes, which have an important role in size-and charge-selective permeability and also in synthesising and maintaining the GBM [2] . Adjacent foot processes interdigitate and form a pore or slit. We show that the downregulation of ALG13-is2 causes actin disorganization, lower expression of nephrin associated with the cellular membrane and, as a consequence, morphological changes of the podocytes and of the slit, which could impair the filtration process.
